替罗非班对非ST段抬高型ACS患者TIMI血流分级及血管内皮功能的影响  

Effect of Tirofiban on TIMI blood flow grading and vascular endothelial function in non-ST segment elevation ACS patients

作　　者：张心雨 冯红霞[1] Zhang Xin-yu;Feng Hong-xia(Zhengzhou People's Hospital,the Fifth Clinical College of Henan University of Chinese Medicine,Zhengzhou 450000,China)

机构地区：[1]河南中医药大学第五临床医学院(郑州人民医院),河南郑州450000

出　　处：《四川生理科学杂志》2024年第1期90-92,共3页Sichuan Journal of Physiological Sciences

摘　　要：目的:探讨替罗非班对非ST段抬高型急性冠脉综合征(NSTE-ACS)患者心肌梗塞溶栓治疗(TIMI)血流分级及血管内皮功能的影响。方法:选择2021年1月至2022年12月我院收治的NSTE-ACS患者62例作为研究对象。按照交替分组法将患者分为对照组和观察组,每组各31例。对照组给予常规阿司匹林+氯吡格雷治疗,观察组在对照组基础上加用替罗非班治疗。分析对比两组的血管内皮功能[一氧化氮(NO)、内皮素(ET)]、TIMI血流分级,以及不良反应。结果:两组治疗后NO水平均较治疗前高,而ET水平较治疗前低,观察组NO水平较对照组高,而ET较对照组低,差异有统计学意义(P<0.05);观察组治疗后TIMI血流分级改善明显优于对照组,差异有统计学意义(P<0.05);两组治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论:替罗非班应用于NSTE-ACS患者中疗效较佳,能够提高TIMI血流分级,改善血管内皮功能,且不会增加不良反应。Objective:To investigate the effects of Tirofiban on blood flow classification and vascular endothelial function of thrombolysis therapy(TIMI)in patients with non-ST segment elevation acute coronary syndrome(NSTE-ACS).Methods:62 patients with NSTE-ACS admitted to our hospital from January 2021 to December 2022 were selected as the study objects.Patients were divided into control group and observation group according to alternate grouping method,with 31 cases in each group.The control group was treated with conventional aspirin plus clopidogrel,and the observation group was treated with tirofiban on the basis of control group.Vascular endothelial function[nitric oxide(NO),endothelin(ET)],TIMI blood flow grading and adverse reactions were analyzed and compared between the two groups.Results:After treatment,the level of NO in both groups was higher than before treatment,while the level of ET was lower.The level of NO in the observation group was higher than that in the control group,and the level of ET was lower than that in the control group,the difference was statistically significant(P<0.05).After treatment,the improvement of TIMI blood grading in observation group was significantly better than that in control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Tirofiban has good efficacy in NSTE-ACS patients,which can improve TIMI blood flow classification and vascular endothelial function without increasing adverse reactions.

关 键 词：非ST段抬高急性冠脉综合征 替罗非班 血流分级 血管内皮功能 

分 类 号：R54[医药卫生—心血管疾病]